Ticker League

Operating Income for Vertex Pharmaceuticals (VRTX)

Latest filings through · Reported

Metric

TTM

$4.78B

YoY change

-2144.1%

5Y CAGR

+10.8%

Peak year (2025)

$4.76B

Operating Income history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: $4.76B

Operating Income growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: -2144.1%

Operating Income history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 2025$4.76B-2144.1%
  • 2024−$232.90M-106.1%
  • 2023$3.83B-11.0%
  • 2022$4.31B+54.8%
  • 2021$2.78B-2.6%
  • 2020$2.86B+138.5%
  • 2019$1.20B+88.5%
  • 2018$635.15M+415.4%
  • 2017$123.24M+1140.4%
  • 2016$9.94M-102.1%
  • 2015−$468.66M-32.3%
  • 2014−$692.41M-23.4%
  • 2013−$903.45M-38841.3%
  • 2012$2.33M-98.0%
  • 2011$113.82M-116.4%
  • 2010−$696.08M+13.5%
  • 2009−$613.41M+32.6%
  • 2008−$462.71M+10.2%
  • 2007−$419.79M+83.3%
  • 2006−$229.04M+52.8%
  • 2005−$149.87M-3.2%
  • 2004−$154.81M-41.5%
  • 2003−$264.53M+121.2%
  • 2002−$119.60M+30.3%
  • 2001−$91.80M+137.3%
  • 2000−$38.68M-2.3%
  • 1999−$39.60M+22.2%
  • 1998−$32.40M+68.8%
  • 1997−$19.20M-35.6%
  • 1996−$29.80M+12.5%
  • 1995−$26.50M+28.0%
  • 1994−$20.70M-1825.0%
  • 1993$1.20M-112.0%
  • 1992−$10.00M+78.6%
  • 1991−$5.60M+36.6%
  • 1990−$4.10M—

Operating Income values are taken from Vertex Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Operating Income at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's current operating income (TTM) is $4.78B. Operating income is profit from core operations: revenue minus cost of goods sold and operating expenses (SG&A, R&D). It excludes interest, taxes, and non-operating items, so it isolates how profitable the business itself is before financing and tax decisions. Compare with EBITDA and net income.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported operating income of $4.76B – plunged 2144.1% year-over-year.

Vertex Pharmaceuticals operating income compound annual growth for the 2020–2025 (5 years) window is +10.8%, with mixed annual results across the window.

Across the available history, operating income reached its high of $4.76B in 2025 and its low of −$903.45M in 2013.

Vertex Pharmaceuticals Operating Income by Year

Vertex Pharmaceuticals Operating Income 2025: $4.76B

Vertex Pharmaceuticals posted operating income of $4.76B in 2025, plunged 2144.1% below 2024. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Operating Income 2024: −$232.90M

In 2024, Vertex Pharmaceuticals reported operating income of −$232.90M, plunged 106.1% below 2023.

Vertex Pharmaceuticals Operating Income 2023: $3.83B

Vertex Pharmaceuticals operating income in 2023 was $3.83B, declined 11.0% below 2022.

Vertex Pharmaceuticals Operating Income 2022: $4.31B

2022's operating income for Vertex Pharmaceuticals came in at $4.31B, surged 54.8% from 2021.

Vertex Pharmaceuticals Operating Income 2021: $2.78B

Vertex Pharmaceuticals operating income in 2021 was $2.78B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Operating Income

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest operating income

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation